Clinical Trial Update: Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating ALS-L1023 for abdominal obesity in metabolic syndrome was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome
• Obesity

Drugs mentioned

• ALS-L1023

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Abdominal Obesity Metabolic Syndrome | Phase 3 | Status: TERMINATED